24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
ADHD
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
09:00
Thoma Bravo cashes in with $372M sale of CyberArk shares after stock surge
09:00
Snyk surpasses $300M in ARR to reach significant growth milestone
21:36
Palo Alto Networks founder Nir Zuk in talks to acquire TV station
15:25
SolarEdge appoints new CEO amid ongoing restructuring efforts
More stories
Buzz
Most popular
Daily
Weekly
1
Tech boom sees six new Israelis join billionaires list
2
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
3
Palo Alto Networks founder Nir Zuk in talks to acquire TV station
4
Who will be Intel’s next CEO? Srouji, Murphy, and Tan lead the pack
5
The Gili Ra’anan model: Questions emerging from Cyberstarts' remarkable success
More news
ADHD
4 stories about ADHD
“There are so few female founders; this has to be put in the past”
21.08.24
|
Ariela Karmel
Eve Mamane, Co-Founder and CRO of mental health startup Agave Health, spoke to CTech about founding her first venture, the need to normalize female founders, and why the tech industry must eliminate outdated limitations on women in leadership roles
Israeli app launches in the U.S. and Israel, helping parents of ADHD children
15.01.24
|
James Spiro
Pery uses clinical data and LLMs to provide advice and analysis for parents managing children diagnosed with attention deficit hyperactivity disorder
“There is a $5 billion opportunity in the ADHD market”
30.01.23
|
CTech
MindTension has raised a total of $2 million for its tool helping diagnose and treat optimization of ADHD and related mental health comorbidities
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
Please ensure Javascript is enabled for purposes of
website accessibility